RecruitingNCT07051850

Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

Studying Multiple myeloma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Sung-Soo Park
Intervention: Bispecific antibody(drug)
Enrollment: 174 enrolled
Eligibility: 19 years · All sexes
Timeline: 2025 – 2025

Study locations (1)

Seoul St. Mary Hospital, Seocho, Seoul, South Korea

Collaborators

Eunpyeong St. Mary's Hospital

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07051850 on ClinicalTrials.gov

Other trials for Multiple myeloma

Additional recruiting or active studies for the same condition.

RECRUITINGNCT07225738
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
City of Hope Medical Center
RECRUITINGPHASE3NCT06980480
A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Takeda
RECRUITINGPHASE4NCT07094048
Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
CHU de Quebec-Universite Laval
RECRUITINGNANCT07226934
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Washington University School of Medicine
RECRUITINGEARLY PHASE1NCT07294625
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
The First Affiliated Hospital with Nanjing Medical University
RECRUITINGPHASE1NCT07179679
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RECRUITINGPHASE3NCT06514508
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Guangzhou Gloria Biosciences Co., Ltd.
RECRUITINGNANCT07359014
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
Second Affiliated Hospital, School of Medicine, Zhejiang University

See all trials for Multiple myeloma →

← Back to all trials